PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

(2017) Melanie Mediavilla-Varela et al.   NEOPLASIA

A review of impedance measurements of whole cells

(2016) Youchun Xu et al.   BIOSENSORS & BIOELECTRONICS

Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent

(2015) Jorge Gandía et al.   BEHAVIOURAL BRAIN RESEARCH

Whole-cell biosensor for label-free detection of GPCR-mediated drug responses in personal cell lines

(2015) Julia M. Hillger et al.   BIOSENSORS & BIOELECTRONICS

A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease

(2015) Tomoyoshi Kondo et al.   CLINICAL NEUROPHARMACOLOGY

Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535)

(2015) Maria Antonietta Stasi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The safety of istradefylline for the treatment of Parkinson’s disease

(2015) Thomas Müller   Expert Opinion On Drug Safety

JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease

(2014) John R. Atack et al.   ACS Chemical Neuroscience

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats

(2014) V. Fernandez-Duenas et al.   Disease Models & Mechanisms

An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease

(2012) Antoni Vallano et al.   CNS & Neurological Disorders-Drug Targets

Conditional neural knockout of the adenosine A2A receptor and pharmacological A2A antagonism reduce pilocarpine-induced tremulous jaw movements: Studies with a mouse model of parkinsonian tremor

(2012) John D. Salamone et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Impedance Responses Reveal β2-Adrenergic Receptor Signaling Pluridimensionality and Allow Classification of Ligands with Distinct Signaling Profiles

(2012) Wayne Stallaert et al.   PLoS One

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

(2011) Susan Duty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Priorities in Parkinson's disease research

(2011) Wassilios G. Meissner et al.   NATURE REVIEWS DRUG DISCOVERY

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

(2011) A. F. Ramlackhansingh et al.   NEUROLOGY

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Treatments for Parkinson disease--past achievements and current clinical needs

(2009) W. Poewe   NEUROLOGY

The clinical progression of Parkinson's disease

(2009) Werner Poewe et al.   PARKINSONISM & RELATED DISORDERS

Adenosine, adenosine A2A antagonists, and Parkinson's disease

(2009) P. Jenner et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease

(2008) Karla M Eggert et al.   CNS DRUGS

An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors

(2008) S. Ferre et al.   CURRENT PHARMACEUTICAL DESIGN

Antagonists of the Human A2AAdenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines

(2008) Roger J. Gillespie et al.   JOURNAL OF MEDICINAL CHEMISTRY

Non-dopaminergic treatments in development for Parkinson's disease

(2008) Susan H Fox et al.   LANCET NEUROLOGY